|
1
|
Ferlay J, Shin HR, Bray F, Forman D,
Mathers C and Parkin DM: Estimates of worldwide burden of cancer in
2008: GLOBOCAN 2008. Int J Cancer. 127:2893–2917. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Xu R, Zhou B, Fung PC and Li X: Recent
advances in the treatment of colon cancer. Histol Histopathol.
21:867–872. 2006.PubMed/NCBI
|
|
3
|
André T, Boni C, Mounedji-Boudiaf L,
Navarro M, Tabernero J, Hickish T, Topham C, Zaninelli M, Clingan
P, Bridgewater J, et al: Oxaliplatin, fluorouracil, and leucovorin
as adjuvant treatment for colon cancer. N Engl J Med.
350:2343–2351. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Raymond E, Chaney SG, Taamma A and
Cvitkovic E: Oxaliplatin: A review of preclinical and clinical
studies. Ann Oncol. 9:1053–1071. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Morales M, Ávila J, González-Fernández R,
Boronat L, Soriano ML and Martín-Vasallo P: Differential
transcriptome profile of peripheral white cells to identify
biomarkers involved in oxaliplatin induced neuropathy. J Pers Med.
4:282–296. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Erlejman AG, De Leo SA, Mazaira GI,
Molinari AM, Camisay MF, Fontana V, Cox MB, Piwien-Pilipuk G and
Galigniana MD: NF-kB transcriptional activity is modulated by
FK506-binding proteins FKBP51 and FKBP52: A role for
peptidyl-prolyl isomerase activity. J Biol Chem. 289:26263–26276.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Gallo LI, Lagadari M, Piwien-Pilipuk G and
Galigniana MD: The 90-kDa heat-shock protein (Hsp90)-binding
immunophilin FKBP51 is a mitochondrial protein that translocates to
the nucleus to protect cells against oxidative stress. J Biol Chem.
286:30152–30160. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li L, Lou Z and Wang L: The role of FKBP5
in cancer aetiology and chemoresistance. Br J Cancer. 104:19–23.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Pei H, Li L, Fridley BL, Jenkins GD,
Kalari KR, Lingle W, Petersen G, Lou Z and Wang L: FKBP51 affects
cancer cell response to chemotherapy by negatively regulating Akt.
Cancer Cell. 16:259–266. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Romano S, D'Angelillo A, Pacelli R,
Staibano S, De Luna E, Bisogni R, Eskelinen EL, Mascolo M, Cali G,
Arra C and Romano MF: Role of FK506-binding protein 51 in the
control of apoptosis of irradiated melanoma cells. Cell Death
Differ. 17:145–157. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Romano S, Staibano S, Greco A, Brunetti A,
Nappo G, Ilardi G, Martinelli R, Sorrentino A, Di Pace A, Mascolo
M, et al: FK506 binding protein 51 positively regulates melanoma
stemness and metastatic potential. Cell Death Dis. 4:e5782013.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Romano S, D'Angelillo A, D'Arrigo P,
Staibano S, Greco A, Brunetti A, Scalvenzi M, Bisogni R, Scala I
and Romano MF: FKBP51 increases the tumour-promoter potential of
TGF-beta. Clin Transl Med. 3:12014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Storer CL, Dickey CA, Galigniana MD, Rein
T and Cox MB: FKBP51 and FKBP52 in signaling and disease. Trends
Endocrinol Metab. 22:481–490. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Hubler TR, Denny WB, Valentine DL,
Cheung-Flynn J, Smith DF and Scammell JG: The FK506-binding
immunophilin FKBP51 is transcriptionally regulated by progestin and
attenuates progestin responsiveness. Endocrinology. 144:2380–2387.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jinwal UK, Koren J III, Borysov SI, Schmid
AB, Abisambra JF, Blair LJ, Johnson AG, Jones JR, Shults CL,
O'Leary JC III, et al: The Hsp90 cochaperone, FKBP51, increases Tau
stability and polymerizes microtubules. J Neurosci. 30:591–599.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Chambraud B, Sardin E, Giustiniani J,
Dounane O, Schumacher M, Goedert M and Baulieu EE: A role for
FKBP52 in Tau protein function. Proc Natl Acad Sci USA.
107:2658–2663. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li L, Fridley B, Kalari K, Jenkins G,
Batzler A, Safgren S, Hildebrandt M, Ames M, Schaid D and Wang L:
Gemcitabine and cytosine arabinoside cytotoxicity: Association with
lymphoblastoid cell expression. Cancer Res. 68:7050–7058. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Varghese F, Bukhari AB, Malhotra R and De
A: IHC Profiler: An open source plugin for the quantitative
evaluation and automated scoring of immunohistochemistry images of
human tissue samples. PLoS One. 9:e968012014. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bleau AM, Agliano A, Larzabal L, de
Aberasturi AL and Calvo A: Metastatic dormancy: A complex network
between cancer stem cells and their microenvironment. Histol
Histopathol. 29:1499–1510. 2014.PubMed/NCBI
|
|
20
|
Ha SY, Yeo SY, Xuan Y and Kim SH: The
prognostic significance of cancer-associated fibroblasts in
esophageal squamous cell carcinoma. PLoS One. 9:e999552014.
View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nalbantoglu IL, Tan BR Jr, Linehan DC, Gao
F and Brunt EM: Histological features and severity of
oxaliplatin-induced liver injury and clinical associations. J Dig
Dis. 15:553–560. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Davies TH, Ning YM and Sánchez ER: A new
first step in activation of steroid receptors: Hormone-induced
switching of FKBP51 and FKBP52 immunophilins. J Biol Chem.
277:4597–4600. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Galigniana MD, Radanyi C, Renoir JM,
Housley PR and Pratt WB: Evidence that the peptidylprolyl isomerase
domain of the hsp90-binding immunophilin FKBP52 is involved in both
dynein interaction and glucocorticoid receptor movement to the
nucleus. J Biol Chem. 276:14884–14889. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Wochnik GM, Rüegg J, Abel GA, Schmidt U,
Holsboer F and Rein T: FK506-binding proteins 51 and 52
differentially regulate dynein interaction and nuclear
translocation of the glucocorticoid receptor in mammalian cells. J
Biol Chem. 280:4609–4616. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Sidler D, Renzulli P, Schnoz C, Berger B,
Schneider-Jakob S, Flück C, Inderbitzin D, Corazza N, Candinas D
and Brunner T: Colon cancer cells produce immunoregulatory
glucocorticoids. Oncogene. 30:2411–2419. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Baughman G, Wiederrecht GJ, Chang F,
Martin MM and Bourgeois S: Tissue distribution and abundance of
human FKBP51, and FK506-binding protein that can mediate
calcineurin inhibition. Biochem Biophys Res Commun. 232:437–443.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Mukaide H, Adachi Y, Taketani S, Iwasaki
M, Koike-Kiriyama N, Shigematsu A, Shi M, Yanai S, Yoshioka K,
Kamiyama Y and Ikehara S: FKBP51 expressed by both normal
epithelial cells and adenocarcinoma of colon suppresses
proliferation of colorectal adenocarcinoma. Cancer Invest.
26:385–390. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Jiang W, Cazacu S, Xiang C, Zenklusen JC,
Fine HA, Berens M, Armstrong B, Brodie C and Mikkelsen T: FK506
binding protein mediates glioma cell growth and sensitivity to
rapamycin treatment by regulating NF-kappaB signaling pathway.
Neoplasia. 10:235–243. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Vandamme M, Pauwels W and Bleecker JD: A
case of delayed oxaliplatin-induced pseudo-obstruction: An atypical
presentation of oxaliplatin neurotoxicity. Acta Clin Belg.
70:207–210. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Calon A, Lonardo E, Berenguer-Llergo A,
Espinet E, Hernando-Momblona X, Iglesias M, Sevillano M,
Palomo-Ponce S, Tauriello DV, Byrom D, et al: Stromal gene
expression defines poor-prognosis subtypes in colorectal cancer.
Nat Genet. 10:320–329. 2015. View
Article : Google Scholar
|
|
31
|
Kuroda N, Nakayama H, Miyazaki E, Toi M,
Hiroi M and Enzan H: The distribution of CD34-positive stromal
cells and myofibroblasts in colorectal carcinoid tumors. Histol
Histopathol. 20:27–33. 2005.PubMed/NCBI
|
|
32
|
Sugimoto H, Mundel TM, Kieran MW and
Kalluri R: Identification of fibroblast heterogeneity in the tumor
microenvironment. Cancer Biol Ther. 5:1640–1646. 2006. View Article : Google Scholar : PubMed/NCBI
|
